2seventy bio, Inc.: management transactions · United States · SEC (Form 4)

About 2seventy bio, Inc.

2seventy bio, Inc. (ticker: TSVT) is a U.S.-based biotechnology company listed on the NASDAQ in the United States. The company operates in advanced cell and gene therapy, with a historical focus on oncology and, more specifically, transformative cancer treatments. 2seventy bio was created in 2021 through a spin-off from bluebird bio, giving it an independent platform dedicated to CAR-T and related next-generation therapeutic approaches. Its headquarters are in Cambridge, Massachusetts, placing it in one of the most important biotech clusters in the U.S. The company’s business has narrowed materially over the past few quarters. While 2seventy bio previously maintained a broader research pipeline across oncology and adjacent areas, management has reallocated resources toward ABECMA® (idecabtagene vicleucel, or ide-cel), its BCMA-targeted CAR-T therapy for multiple myeloma. In the United States, ABECMA is jointly developed and commercialized with Bristol Myers Squibb under a co-development, co-promotion, and profit-sharing arrangement. Outside the United States, Bristol Myers Squibb retains sole responsibility for manufacturing and commercialization. As a result, ABECMA has become the company’s core strategic and financial asset. From a competitive standpoint, 2seventy bio operates in a highly capital-intensive and scientifically demanding segment, where the competitive landscape is shaped by a small number of large oncology-cell-therapy players and by the ability of major pharmaceutical companies to fund manufacturing, commercialization, and clinical development at scale. In this environment, the investment case for TSVT has been closely tied to ABECMA’s clinical differentiation, market uptake, and the durability of its role in multiple myeloma therapy relative to other biologics and cell therapies. Recent milestones have been significant. During 2024, the company continued its strategic simplification by divesting portions of its R&D portfolio, including assets transferred to Regeneron, and by concentrating almost entirely on ABECMA. In 2025, 2seventy bio announced a definitive merger agreement under which Bristol Myers Squibb would acquire all outstanding shares for $5.00 per share in an all-cash transaction, underscoring the strategic importance of the company’s principal asset to its partner. For investors, TSVT should be viewed as a specialized NASDAQ-listed U.S. biotech story whose profile is driven by commercial execution, partnership economics, and transaction news rather than by a broad diversified pipeline.